相关临床试验
5
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2016
已完成
5
100.0%
暂无批准数据
- Outer Biosciences, co-founded by Michael Polansky, has developed a proprietary perfusion and bioreactor system that keeps living human skin tissue viable ex vivo for up to four weeks, far beyond the industry norm of days. - The company trains AI models directly on real-time biological responses of living skin, generating a new candidate ingredient roughly every six weeks, with six leads currently active in its pipeline. - Rather than building a consumer brand, Outer Biosciences plans to license or sell its AI-discovered cosmetic ingredients to beauty and pharma partners, with four of six current leads likely to reach commercialization. - The platform could reduce reliance on animal testing and accelerate dermatological drug development, with applications spanning anti-aging, eczema, and wound healing.
- Ultrasmall fluorescent core-shell silica nanoparticles (C' dots) selectively killed aggressive prostate cancer cells while sparing healthy tissue in a preclinical mouse study. - The nanoparticles triggered ferroptosis, a specialized form of oxidative cell death, and transformed immunologically "cold" tumors into immune-active "hot" tumors. - Combining nanoparticles with immune checkpoint blockade produced complete or near-complete remissions and indefinite survival in four out of ten mice. - Researchers plan to advance the technology toward human clinical trials to evaluate safety and effectiveness as a potential new class of cancer therapy.
- 3T Biosciences appointed Behzad Kharabi, M.D., as chief medical officer, bringing extensive experience from leading the development of CD19 CAR-T therapy TECARTUS® for blood cancers. - Karen E. Knudsen, MBA, Ph.D., CEO of the Parker Institute for Cancer Immunotherapy, joined the company's board of directors to provide strategic guidance. - The appointments strengthen 3T's capabilities as it advances bispecific T-cell engager therapeutics targeting solid tumors, addressing unmet medical needs in immuno-oncology. - Both leaders emphasized the company's novel approach to discovering druggable T-cell receptor targets with enhanced specificity for improved potency and safety.
- Cornell researchers discovered that ultrasmall silica nanoparticles called C'dots can reprogram immune-resistant tumor microenvironments, transforming "cold" tumors into "hot" ones that respond better to immunotherapy. - The nanoparticles activate multiple anti-tumor mechanisms simultaneously, including stimulating innate immune responses, inducing cell-cycle arrest, and reprogramming T cells and macrophages to attack cancer more effectively. - In mouse models, combining C'dots with immunotherapies targeting immune checkpoints and cytokines led to significant survival advantages compared to immunotherapy alone. - The approach shows promise beyond melanoma, with similar immune-activating effects observed in prostate and ovarian cancer models, suggesting broad therapeutic potential.
- UbiVac's DPV-001 cancer vaccine demonstrated a 3x improvement in response rates and progression-free survival compared to standard-of-care immunotherapy in head and neck squamous cell carcinoma patients. - The "off-the-shelf" immunotherapy contains over 400 Dark Matter-derived antigens designed to target virtually all solid tumors, with more than 34 patients treated to date. - Clinical data showed a 2x improvement in overall survival, 56% response rate in PD-1-naïve patients versus 19% standard-of-care, and 33% response rate in patients who previously failed anti-PD-1 therapy. - UbiVac plans to initiate a Phase II trial targeting the difficult-to-treat population of patients who failed prior anti-PD-1 therapy, representing a key value inflection point for the company.
- Nigeria has launched the Innovative Cancer Medicine Demonstration Project at National Hospital Abuja, marking the first time advanced cancer immunotherapy will be administered in a structured feasibility study in Sub-Saharan Africa. - The program provides free nivolumab treatment to 30 patients with metastatic colorectal cancer, with full costs estimated at over seven billion naira sponsored by international partners including Bristol Myers Squibb, Roche, and the Parker Institute for Cancer Immunotherapy. - The initiative represents a collaboration between the Federal Government, Clinton Health Access Initiative, and pharmaceutical partners to demonstrate that Nigeria has the infrastructure and expertise to safely deliver advanced cancer treatment. - Success of this feasibility study could pave the way for including immunotherapy in Nigeria's National Health Insurance scheme and establishing cost negotiations for broader access across Africa.
- Charles River Laboratories has announced two strategic collaborations to advance oncology research, including an alliance with the Parker Institute for Cancer Immunotherapy and support for Children's Hospital Los Angeles Phase I clinical trials. - The partnership with PICI will provide network members access to Charles River's comprehensive preclinical drug discovery and development services, from early discovery through manufacturing. - Children's Hospital Los Angeles received a $6 million award from the California Institute for Regenerative Medicine in 2024 to develop innovative stem cell approaches for treating recurrent solid tumors in children and adolescents. - Charles River's cell and gene therapy CDMO capabilities will support streamlined manufacturing processes to accelerate the development of cancer treatments for pediatric patients.
- UCLA researchers have developed AlloCAR70-NKT, an innovative off-the-shelf immunotherapy that uses genetically engineered natural killer T cells to target CD70 protein on kidney cancer cells without requiring patient-specific customization. - The therapy demonstrated a multi-pronged attack mechanism in preclinical models, directly killing cancer cells, disrupting the tumor microenvironment, and eliminating immune cells that would normally reject donor cells. - This approach addresses critical limitations of traditional CAR-T therapies in solid tumors, offering potential benefits for metastatic renal cell carcinoma patients who face a five-year survival rate of just 12%. - The stem cell-derived therapy overcomes time delays and safety risks associated with current immunotherapies, particularly for patients with aggressive, late-stage disease.
- The RADIOHEAD study validated Guardant Reveal, a methylation-based liquid biopsy assay, for earlier detection of immunotherapy response in over 500 patients with advanced solid tumors across multiple cancer types. - Patients with an 80% or greater decrease in circulating tumor DNA showed a 75% lower risk of disease progression, while the assay identified treatment failure up to 5 months before standard imaging methods. - The tissue-free monitoring technology could enable oncologists to make faster treatment decisions, potentially sparing patients from ineffective therapies and improving clinical outcomes in immunotherapy management.
- Dispatch Bio, a new biotech company formed through collaboration between Arch Venture Partners and the Parker Institute for Cancer Immunotherapy, has raised $216 million to develop a universal solid tumor treatment approach. - The company's lead therapy combines gene therapy, immunotherapy, and cell therapy by using engineered viruses to tag cancer cells with a synthetic "flare" antigen that CAR-T cells can then target and destroy. - Founded by renowned researchers including University of Pennsylvania's Carl June and Stanford's Chris Garcia, the approach aims to overcome current limitations of checkpoint inhibitors and CAR-T therapies in treating solid tumors. - The therapy is expected to enter clinical testing next year and could potentially address the challenge that many "cold" tumors pose to existing immunotherapies.
